Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$48.44M+35.3%-$74.92M-4.1%-$72.01M-315%-$17.36M+56.1%-$39.53M+57.1%
$62K+5.1%$59K-7.8%$64K+42.2%$45K-13.5%$52K+2.0%
$18M+28.4%$14.02M-6.6%$15.01M-1.1%$15.18M-0.2%$15.21M+61.6%
-$30.6M+25.1%-$40.88M-24.7%-$32.77M+13.0%-$37.67M-3.3%-$36.47M+2.7%
$38K-62.0%$100K+138%$42K-52.3%$88K+450%$16K+433%
-$11.51M+45.6%-$21.14M$0+100%-$159.14M-5,674%$2.86M+105%
$11.07M-19.1%$13.68M+132%$5.89M+72.0%$3.43M-47.5%$6.52M-98.6%
-$31.05M+35.8%-$48.33M-98.3%-$24.37M+87.4%-$193.38M-614%-$27.09M-108%
-$30.64M+25.2%-$40.98M-24.9%-$32.81M+13.1%-$37.76M-3.5%-$36.48M+2.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does NewAmsterdam Pharma Company's cash flow data come from?
Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.